Exane Derivatives’s Oscar Health OSCR Stock Holding History

Exane Derivatives’s Portfolio OSCR Stock Details OSCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-21,725	Closed	-$217K	–	883
2022 Q1	$217K	Sell	21,725 -2,504	-10%	-$18.6K	0.06%	310
2021 Q4	$190K	Buy	+24,229	New	+$304K	0.05%	342

Other funds holding OSCR

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

GCGM

General Catalyst Group Management Cambridge, Massachusetts $189M AUM 10.96% 1-Year Est. Return

VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return

SAM

Southeastern Asset Management Memphis, Tennessee $1.92B AUM 6.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCMNY

Thrive Capital Management (New York) New York $3.81B AUM 45.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LGI

Lakestar Growth I St. Peter Port, Guernsey $11.5M AUM 71.31% 1-Year Est. Return

Exane Derivatives's OSCR Position: Q2 2022 in Review

Exane Derivatives sold out of Oscar Health (OSCR) in Q2 2022, closing a stake of 21,725 shares — an estimated $217K sold.

Exane Derivatives first reported a position in OSCR in Q4 2021 and held it in 2 quarters. The position peaked at $217K in Q1 2022. 129 funds tracked by Wall St. Rank hold OSCR as of Q2 2022.

Exane Derivatives reported no remaining Oscar Health position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 21,725 Oscar Health shares in Q2 2022, an estimated $217K.
Exane Derivatives first reported a position in Oscar Health in Q4 2021 and held it in 2 quarters.
Exane Derivatives's Oscar Health position peaked at $217K in Q1 2022.
129 funds tracked by Wall St. Rank held Oscar Health as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.